Astria Therapeutics, Inc. has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $125,000,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Astria Therapeutics, Inc. is raising $125,000,000.00 in new funding. About Astria Therapeutics, Inc.: Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
To learn more about Astria Therapeutics, Inc., visit http://astriatx.com/
Contact:
Jill Milne, President and Chief Executive Officer
617-349-1971
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.